Cartalax Research Guide

Full name: Cartalax (Ala-Glu-Asp-Gly Cartilage Bioregulator)

A short synthetic peptide bioregulator from the Khavinson family targeted at cartilage and connective/musculoskeletal tissue. Used in the bioregulator community for joint and cartilage support in short repeated courses.

How Cartalax Works

As a signal peptide (Ala-Glu-Asp-Gly), it is proposed to regulate gene expression in chondrocytes and connective tissue, supporting cartilage matrix maintenance and anti-inflammatory tissue signaling.

Dosing Protocol

• Typical dose: ~1-2 capsules/day or short injectable courses
• Frequency: Once daily
• Duration: 10-30 day courses
• Route: Oral capsule or subcutaneous

Reported Benefits

• Cartilage/joint tissue support
• Connective tissue maintenance (proposed)
• Anti-inflammatory tissue signaling
• Short course-based protocol

Potential Side Effects

• Limited Western clinical data
• Injection site reactions (injectable)
• Unknown long-term effects

Research Citations

1. Cartilage peptide bioregulators (2015) - Reported to support chondrocyte function and cartilage tissue in regional research studies.

Related Pain & Inflammation Compounds

• Low-Dose Naltrexone (LDN) - Full Profile
• PEA - Full Profile
• Diclofenac Topical - Full Profile
• Pentosan (Joint Pain) - Full Profile
• ARA-290 - Full Profile
• Boswellia (AKBA) - Full Profile

View full Cartalax profile with 3D molecule viewer →